Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Latest 13D and 13G Filings > 13D Filing (0000929638-22-001419)

Filing Details

Accession Number:
0000929638-22-001419
Form Type:
13D Filing
Publication Date:
2022-09-20 20:00:00
Filed By:
Nsv Investments I, L.p.
Company:
Ventyx Biosciences Inc.
Filing Date:
2022-09-21
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
NSV Investments I 0 5,873,225 0 5,873,225 5,873,225 10.4%
NSV Partners III 0 12,239,954 0 12,239,954 12,239,954 21.8%
NSV Partners III GP 0 12,239,954 0 12,239,954 12,239,954 21.8%
Somasundaram Subramaniam 0 16,892,528 0 16,892,528 16,892,528 30.0%
NSV Partners II 0 2,894,887 0 2,894,887 2,894,887 5.1%
Filing

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Ventyx Biosciences, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

92332V107

(CUSIP Number)

Somasundaram Subramaniam

New Science Ventures

500 West Putnam Avenue, Suite 400

Greenwich, CT 06830

(212) 688-5100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

with a copy to:


Leland S. Benton
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
(202) 739-3000
September 17, 2022
(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 92332V107

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

 
  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

     8   

  SHARED VOTING POWER

 

  5,873,225

   10   

  SHARED DISPOSITIVE POWER

 

  5,873,225

14  

  TYPE OF REPORTING PERSON (See Instructions)

 

  PN

 

1
Percentage calculated based on 50,917,801 shares of the common stock, par value $0.0001 per share (the “Common Stock”) of Ventyx Biosciences, Inc. (the “Issuer”) outstanding as of August 10, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 15, 2022, and a further 5,350,000 shares of Common Stock issued by the Issuer on September 20, 2022, as disclosed by the Issuer in its press release dated September 19, 2022.
CUSIP No. 92332V107







  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

 
  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware





     8   

  SHARED VOTING POWER

 

  12,239,954

   10   

  SHARED DISPOSITIVE POWER

 

  12,239,954





14  

  TYPE OF REPORTING PERSON (See Instructions)

 

  PN

 

1
Percentage calculated based on 50,917,801 shares of Common Stock outstanding as of August 10, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Commission on August 15, 2022, and a further 5,350,000 shares of Common Stock issued by the Issuer on September 20, 2022, as disclosed by the Issuer in its press release dated September 19, 2022.

CUSIP No. 92332V107








  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

 
  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware





     8   

  SHARED VOTING POWER

 

  12,239,954

   10   

  SHARED DISPOSITIVE POWER

 

  12,239,954





14  

  TYPE OF REPORTING PERSON (See Instructions)

 

  OO

 

1
Percentage calculated based on 50,917,801 shares of Common Stock outstanding as of August 10, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Commission on August 15, 2022, and a further 5,350,000 shares of Common Stock issued by the Issuer on September 20, 2022, as disclosed by the Issuer in its press release dated September 19, 2022.

CUSIP No. 92332V107








  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

 
  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  USA





     8   

  SHARED VOTING POWER

 

  16,892,528

   10   

  SHARED DISPOSITIVE POWER

 

  16,892,528





14  

  TYPE OF REPORTING PERSON (See Instructions)

 

  IN

 

1
Percentage calculated based on 50,917,801 shares of Common Stock outstanding as of August 10, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Commission on August 15, 2022, and a further 5,350,000 shares of Common Stock issued by the Issuer on September 20, 2022, as disclosed by the Issuer in its press release dated September 19, 2022.

CUSIP No. 92332V107








  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

 
  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware





     8   

  SHARED VOTING POWER

 

  2,894,887

   10   

  SHARED DISPOSITIVE POWER

 

  2,894,887





14  

  TYPE OF REPORTING PERSON (See Instructions)

 

  PN

 

1
Percentage calculated based on 50,917,801 shares of Common Stock outstanding as of August 10, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Commission on August 15, 2022, and a further 5,350,000 shares of Common Stock issued by the Issuer on September 20, 2022, as disclosed by the Issuer in its press release dated September 19, 2022.

CUSIP No. 92332V107


This Amendment No. 1 (“Amendment No. 1”) amends the Statement of Beneficial Ownership on Schedule 13D jointly filed with the Commission by NSV Investments I, L.P., a Delaware limited partnership, NSV Partners III, LP, a Delaware limited partnership, NSV Partners III GP, LLC, a Delaware limited liability company, NSV Partners II, LLC, a Delaware limited liability company and Somasundaram Subramaniam, a United States citizen on October 29, 2021 (the “Schedule 13D”), with respect to the Common Stock. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D, which remains unchanged.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Item 6 is hereby amended and supplemented to include the following:
On September 17, 2022, Mr. Subramaniam and each of the NSV funds entered into a “lock-up” agreement (collectively, the “Lock-Up Agreements”) with Morgan Stanley & Co. LLC, Jefferies LLC, Piper Sandler & Co. and LifeSci Capital LLC. Pursuant to the terms of the Lock-Up Agreements, Mr. Subramaniam and the NSV funds have agreed that, subject to certain exceptions, they will not, during the period beginning on September 17, 2022 and continuing through the close of trading on the date that is two trading days immediately following the Issuer’s public release of earnings for its third quarter ending September 30, 2022, (i) sell or offer to sell any shares of Common Stock or securities convertible into or exercisable or exchangeable for the same, owned either of record or beneficially (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), (ii) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of shares of the Common Stock or securities convertible into or exercisable or exchangeable for the same, (iii) make any demand for, or exercise any right with respect to, the registration under the Securities Act of 1933, as amended, of the offer and sale of any shares of Common Stock or securities convertible into or exercisable or exchangeable for the same, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration or (iv) publicly announce any intention to do any of the foregoing.
The foregoing summary of the Lock-Up Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of Lock-Up Agreement, a copy of which is attached hereto as Exhibit C and is incorporated by reference into this Item 6.

Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended and supplemented to include the following exhibit:

     
Exhibit
  
Description
   
C
  
Form of Lock-Up Agreement (incorporated by reference to Exhibit B of Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on September 19, 2022).



CUSIP No. 92332V107

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 20, 2022

 



Name:   Tom Lavin


Name:   Tom Lavin





Name:   Somasundaram Subramaniam


Name:   Tom Lavin

 

*

This reporting person disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 10001).